Current Headlines

  1. BeiGene Receives U.S. FDA Breakthrough Therapy Designation For Zanubrutinib In Mantle Cell Lymphoma
    1/14/2019

    BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its investigational Bruton’s tyrosine kinase (BTK) inhibitor, zanubrutinib, for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy

  2. GenScript Launches Novel Technology Licensed From Amgen For Accelerating Protein And Antibody Purification
    1/14/2019

    GenScript®, the world's leading gene synthesis provider, announced today at PepTalk that it has launched the AmMag™ SA semi-automatic purification instrument, a novel technology that accelerates and simplifies protein and antibody purification, reducing the process from days to hours

  3. Charles River Laboratories And Atomwise Form A Strategic Alliance To Provide Integrated, Artificial Intelligence-Driven Drug Discovery
    1/11/2019

    Charles River Laboratories International, Inc. and Atomwise, Inc. recently announced the formation of a strategic alliance that offers clients access to Atomwise’s artificial intelligence (AI)-powered, structure-based, drug design technology, which allows scientists to predict how well a small molecule will bind to a target protein of interest

  4. Ocular Therapeutix Submits Supplemental New Drug Application (sNDA) For DEXTENZA (Dexamethasone Ophthalmic Insert) For The Treatment Of Ocular Inflammation Following Ophthalmic Surgery
    1/10/2019

    Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for DEXTENZA (dexamethasone ophthalmic insert)

  5. Aptamer Group Announces Agreement With AstraZeneca To Explore Next-Generation Drug Delivery Devices
    1/10/2019

    Aptamer Group recently announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney. The two-year agreement will give AstraZeneca use of Aptamer Group’s proprietary technology to explore the feasibility of developing the next generation of drug delivery vehicles, called Aptamer Drug Conjugates (ApDCs)

  6. Elevian And Insilico Enter A Research Collaboration To Discover Drugs That Target Aging
    1/9/2019

    On the final day of the largest biotechnology and pharmaceutical partnering week at the Juvenescence Longevity Showcase two leading longevity biotechnology companies, Elevian and Insilico Medicine, announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets

  7. Novartis Investigational Therapy Crizanlizumab (SEG101) Receives FDA Breakthrough Therapy Designation For The Prevention Of Vaso-Occlusive Crises In Sickle Cell Disease
    1/8/2019

    Novartis announced today that the US Food and Drug Administration (FDA) has granted crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease (SCD)

  8. FUJIFILM Cellular Dynamics, Inc. Launches New Product iCell Microglia, An iPSC-Derived Neural Cell Type
    1/8/2019

    FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and tissue-specific cells differentiated from iPSCs, has announced the launch of its newest product, iCell® Microglia. Microglia are the immune cells of the central nervous system responsible for fundamental physiological and pathological processes

  9. LSTM And UoL Researchers Design New Anti-Wolbachia Drug With Potential To Treat Onchocerciasis And Lymphatic Filariasis
    1/8/2019

    Researchers from LSTM and the University of Liverpool have successfully optimised a hit from a whole cell screening of a 10000-compound library to deliver the first novel fully synthetic and rationally designed anti-Wolbachia drug, AWZ1066S, which could potentially be used to treat onchocerciasis and lymphatic filariasis (LF)

  10. New Drug Has Potential To Treat River Blindness And Elephantiasis
    1/8/2019

    Researchers from the University of Liverpool and Liverpool School of Tropical Medicine have successfully optimised a hit from a whole cell screening of a 10000-compound library to deliver the first novel fully synthetic and rationally designed anti-Wolbachia drug, AWZ1066S, which could potentially be used to treat onchocerciasis and lymphatic filariasis